Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.4% – Time to Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price fell 6.4% during trading on Wednesday . The company traded as low as $19.93 and last traded at $19.74. 329,516 shares changed hands during trading, a decline of 57% from the average session volume of 763,110 shares. The stock had previously closed at $21.09.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Trading Down 6.1 %

The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -26.77 and a beta of -2.75. The stock’s 50 day moving average is $26.97 and its two-hundred day moving average is $33.83.

Institutional Trading of Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Deep Track Capital LP raised its stake in Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after buying an additional 1,579,492 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Structure Therapeutics by 196.5% during the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after acquiring an additional 820,589 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after buying an additional 602,609 shares in the last quarter. Vestal Point Capital LP raised its stake in Structure Therapeutics by 105.4% in the third quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after purchasing an additional 590,000 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in Structure Therapeutics in the fourth quarter worth approximately $13,560,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.